Headlines in Reproductive Medicine

The following links have been gleaned from current news to help keep you informed on reproductive medicine's impact on our world. Note:  Some newspapers and periodicals require free registration to access their online articles. The links on this page may expire within a week of posting; however, most news web sites keep online archives with articles offered either free or available for purchase. WARNING! THE ASRM HAS NOT REVIEWED THE CONTENTS OF THE EXTERNAL WEB SITES LISTED ON THIS PAGE, NOR CAN WE ENDORSE THEM OR THE VIEWS EXPRESSED WITHIN.  

Eggs Unlimited

Headlines in Reproductive Medicine November 06, 2015

OvaScience is preoccupied by an enduring mystery in human biology—why eggs fail—and the palpable hope that we can do something about it. On the company's homepage, a beautiful, smiling woman with red hair tumbling down her shoulders gazes at something off-screen. “A woman's biology is extraordinary,” the tagline reads. Venture capitalists fueled OvaScience with $40 million soon after it launched in 2011, and it raised more than $200 million after going public a year later.

Scientists Could One Day Create Genetically Modified ‘Designer Babies’ — But Should They?

Headlines in Reproductive Medicine June 18, 2015

This week, the Congressional Research and Technology Subcommittee held its first hearing on the science and ethics of genetically modifying human DNA. The main topic up for discussion was CRISPR, the world’s most promising and widely applicable gene-editing technique. So far, CRISPR (pronounced crisper) has been used by multiple labs around the world to modify the genes of organisms as varied as bacteria, plants, mice and some primates. But what lawmakers wanted to talk about with scientists this week is what it will mean when we start making genetic improvements to human beings.

FDA to Again Consider Drug Aimed at Women’s Sexual Dysfunction

Headlines in Reproductive Medicine June 04, 2015

The Food and Drug Administration said that safety concerns outweighed any benefits, and, in 2013, again rejected the drug for approval.The manufacturer, Sprout Pharmaceuticals resubmitted an application for approval in February with additional safety studies.And on Thursday, an advisory committee of the FDA will again examine the risks and rewards of the drug. Their vote could influence the final FDA decision, due in August.  

Back to Top